Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ErbB receptor family comprises four structurally related RTKs central to growth factor signaling, whose dysregulation drives many human cancers through aberrant activation of proliferation/survival/migration pathways. Their modular structure enables complex regulation via diverse ligands/dimers/adaptor protein interactions—making them prime targets for anti-cancer therapies.
Inhibition of receptor tyrosine kinase activity, blockade of ligand binding, prevention of dimerization, antibody-dependent cell-mediated cytotoxicity (ADCC)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ErbB Receptor (ErbB).